IFN-β-1a, (Avonex®)

TERMINATED · · Relapsing-Remitting Multiple Sclerosis

rate of enrollment

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.